Search Results

Steady-State Pharmacokinetic Comparison of a New, Extended-Release, Once-Daily Morphine Formulation, Avinza&unknown;, and a Twice-Daily Controlled-Release Morphine Formulation in Patients with Chronic Moderate-to-Severe Pain

Authors: Portenoy R.K.; Sciberras A.; Eliot L.; Loewen G.; Butler J.; Devane J.

Source: Journal of Pain and Symptom Management, Volume 23, Number 4, April 2002 , pp. 292-300(9)

Publisher: Elsevier

Efficacy and Safety of a Once-Daily Morphine Formulation in Chronic, Moderate-to-Severe Osteoarthritis Pain - Results from a Randomized, Placebo-Controlled, Double-Blind Trial and an Open-Label Extension Trial

Authors: Caldwell J.R.; Rapoport R.J.; Davis J.C.; Offenberg H.L.; Marker H.W.; Roth S.H.; Yuan W.; Eliot L.; Babul N.; Lynch P.M.; for the Avinza&unknown; TRG004-04 Study Group

Source: Journal of Pain and Symptom Management, Volume 23, Number 4, April 2002 , pp. 278-291(14)

Publisher: Elsevier

Pharmacokinetics and pharmacodynamics of twenty-four-hourly Kapanol compared to twelve-hourly MS Contin in the treatment of severe cancer pain

Authors: Gourlay G.K.; Cherry D.A.; Onley M.M.; Tordoff S.G.; Conn D.A.; Hood G.M.; Plummer J.L.

Source: Pain, Volume 69, Number 3, February 1997 , pp. 295-302(8)

Publisher: Elsevier

Multiple-dose pharmacokinetic evaluation of two formulations of sustained-release morphine sulfate tablets

Authors: Schobelock M.J.; Shepard K.V.; Mosdell K.W.; Lee J.; Hulse J.D.

Source: Current Therapeutic Research, Volume 56, Number 10, October 1995 , pp. 1009-1021(13)

Publisher: Elsevier

Control of Cancer-Related Pain with MS Contin(R): A Comparison Between 12-Hourly and 8-Hourly Administration

Authors: Mignault G.G.; Latreille J.; Viguie F.; Richer P.; Lemire F.; Harsanyi Z.; Stewart J.H.

Source: Journal of Pain and Symptom Management, Volume 10, Number 6, August 1995 , pp. 416-422(7)

Publisher: Elsevier